

FILE

Sheet 01 of 13

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

Applicant

Ashkenazi et al.

Filing Date


21 Jun 2001

Group

164.6
~~To Be Assigned~~

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>clm</i>	*	1 3,691,016	12.09.72	Patel, R.			
	*	2 3,969,287	13.07.76	Jaworek et al.			
	*	3 4,179,337	18.12.79	Davis et al.			
	*	4 4,195,128	25.03.80	Hildebrand et al.			
	*	5 4,229,537	21.10.80	Hodgins et al.			
	*	6 4,247,642	27.01.81	Hirohara et al.			
	*	7 4,301,144	17.11.81	Iwashita et al.			
	*	8 4,330,440	18.05.82	Ayers et al.			
	*	9 4,342,566	03.08.82	Theofilopoulos et al.			
	*	10 4,399,216	16.08.83	Axel et al.			
	*	11 4,419,446	06.12.83	Howley et al.			
	*	12 4,496,689	29.01.85	Mitra, G.			
	*	13 4,601,978	22.07.86	Karin, M.			
	*	14 4,640,835	03.02.87	Shimizu et al.			
	*	15 4,670,417	02.06.87	Iwasaki et al.			
	*	16 4,676,980	30.06.87	Segal et al.			
	*	17 4,736,866	12.04.88	Leder et al.			
	*	18 4,791,192	13.12.88	Nakagawa et al.			
	*	19 4,816,567	28.03.89	Cabilly et al.			
	*	20 4,870,009	26.09.89	Evans et al.			
	*	21 4,965,199	23.10.90	Capon et al.			
	*	22 5,010,182	23.04.91	Brake et al.			
	*	23 5,364,934	15.11.94	Drayna et al.			
	*	24 5,763,223	09.06.98	Wiley et al.			
<i>an</i>	*	25 60/035,496					14.01.97
	*	26 60/054,885	07.08.99				

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>an</i>	*	27 EP 0 867 509	30.09.98	EP			
	*	28 0,003,089 A1	25.07.79	EPO (ENGLISH ABSTRACT ATTACHED)			
<i>an</i>	*	29 036,776 A2	30.09.81	EPO			
	*	30 073,657	09.03.83	EPO			
	*	31 117,058 A2	29.08.84	EPO			
	*	32 117,060 A2	29.08.84	EPO			
<i>an</i>	*	33 125,023 A1	14.11.84	EPO			

Examiner

Clare M. B.

Date Considered

9/27/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)


Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

1646
~~To Be Assigned~~

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
Cur ↓ cur	* 34	173,494	05.03.86	EPO				
	* 35	321,196	21.06.89	EPO				
	* 36	362,179 A2	04.04.90	EPO				
	* 37	417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	* 38	EP 0 911 633	28.04.99	EPO				
	* 39	266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)				
	* 40	WO 00/71150	30.11.00	PCT				
	* 41	WO 87/05330	11.09.87	PCT				
	* 42	WO 89/02922	06.04.89	PCT				
	* 43	WO 89/05859	29.06.89	PCT				
	* 44	WO 89/06692	27.07.89	PCT				
	* 45	WO 90/13646	15.11.90	PCT (ENGLISH ABSTRACT ATTACHED)				
	* 46	WO 91/00358	10.01.91	PCT				
	* 47	WO 91/00360	10.01.91	PCT				
	* 48	WO 92/20373	26.11.92	PCT				
	* 49	WO 93/08829	13.05.93	PCT				
	* 50	WO 94/04679	03.03.94	PCT				
	* 51	WO 94/04690	03.03.94	PCT				
	* 52	WO 94/29348	22.12.94	PCT				
	* 53	WO 98/30693	16.07.93	PCT				
	* 54	WO 98/58062	23.12.98	PCT				
	* 55	WO 99/00423	07.01.99	PCT				
	* 56	WO 99/09165	25.02.99	PCT				
	* 57	WO 99/11791	11.03.99	PCT				
	* 58	WO 99/12963	18.03.99	PCT				
	* 59	2,211,504	05.07.89	UNITED KINGDOM				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Cur	* 60	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for μ , α , γ 1, γ 2a, and γ 3 chains" <u>Biochemistry</u> 19:2711-2719 (1980)
	* 61	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
	* 62	Aplin and Wriston, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)
	* 63	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoconjugate" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
Cur	* 64	Baldwin, A., "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)

Examiner

Claire M. Keef

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

164.6
To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CU	* 65	Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" <u>Cell</u> 33:729-740 (July 1983)
	* 66	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	* 67	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
	* 68	Bianchi et al., "Transformation of the yeast <i>Kluyveromyces lactis</i> by New Vectors Derived from the 1.6 μ m Circular Plasmid pKD1" <u>Curr. Genet.</u> 12:185-192 (1987)
	* 69	Biely et al., "A New Chromogenic Substrate for Assay and Detection of α -Amylase" <u>Analytical Biochemistry</u> 172:176-179 (1988)
	* 70	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	* 71	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
	* 72	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)
	* 73	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)
	* 74	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)
	* 75	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-152 (1987)
	* 76	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	* 77	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
	* 78	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
	* 79	Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" <u>Year in Immunology</u> 7:33-40 (1993)
	* 80	Byrn et al., "Biological Properties of a CD4 Immunoaderhin" <u>Nature</u> 344:667-670 (April 12, 1990)
	* 81	Canaani et al., "Regulated Expression of Human Interferon β 1 Gene After Transduction into Cultured Mouse and Rabbit Cells" <u>Proc. Natl. Acad. Sci. USA</u> 79:5166-5170 (September 1982)
	* 82	Capon et al., "Designing CD4 Immunoaderhins for AIDS Therapy" <u>Nature</u> 337:525-531 (1989)
	* 83	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)
CN	* 84	Carter, P. et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992)

Examiner

Chen N. K.

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1110P1C1	Serial No. 09/887,879
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 21 Jun 2001	Group 1646 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
CU	* 85	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)			
	* 86	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)			
	* 87	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)			
	* 88	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)			
	* 89	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)			
	* 90	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)			
	* 91	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)			
	* 92	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)			
	* 93	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)			
	* 94	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)			
	* 95	Creighton,, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)			
	* 96	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)			
	* 97	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ" <u>European Journal of Immunology</u> 17:689-693 (1987)			
	* 98	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)			
CU	* 99	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)			
CU	*100	Degli-Esposti et al., "The Novel Receptor-TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7:813-820 (1997)			
CU	*101	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Mol. Appl. Gen.</u> 1:561-573 (1982)			
	*102	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press pps. 1-16;133-142 (1995)			
	*103	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas" <u>Proc. Natl. Acad. Sci. USA</u> 77(10):6027-6031 (1980)			
CU	*104	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" <u>Journal of Biological Chemistry</u> 257:3105-3109 (1982)			
Examiner <i>Chen M. K.</i>				Date Considered 9/17/02	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

164.6
~~To Be Assigned~~

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Can	*105	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)
	*106	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)
	*107	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)
	*108	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)
	*109	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)
	*110	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" <u>Nature</u> 273:113-120 (May 11, 1978)
	*111	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <i>Kluyveromyces</i> Yeasts" <u>Bio/Technology</u> 9:968-975 (1991)
	*112	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)
	*113	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)
	*114	Gething and Sambrook, "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)
	*115	Gietz et al., "Improved Method for High Efficiency Transformation of Intact Yeast Cells" <u>Nucleic Acids Research</u> 20(6):1425 (1992)
	*116	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)
	*117	Goeddel et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)
	*118	Goeddel et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> " <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)
	*119	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol</u> 7:R750-R753 (1997)
	*120	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
	*121	Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" <u>Proc. Natl. Acad. Sci. USA</u> 79:6777-6781 (November 1982)
	*122	Gough et al., "Molecular cloning of seven mouse immunoglobulin κ chain messenger ribonucleic acids" <u>Biochemistry</u> 19:2702-2710 (1980)
	*123	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
ar	*124	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)

Examiner

Claus M. K.

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce

Atty Docket No.

Serial No.

P1110P1C1

09/887,879

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

1646
~~To Be Assigned~~

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

ac	*125	Gray et al., "Expression of Human Immune Interferon cDNA in E. coli and Monkey Cells" <u>Nature</u> 295:503-508 (February 11, 1982)
	*126	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" <u>Gene</u> 18:355-360 (1982)
	*127	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
	*128	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
	*129	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York: Pergamon Press Vol. 7:149-167 (1968)
	*130	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)
	*131	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
	*132	Holland and Holland, "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)
	*133	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V μ gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
	*134	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
	*135	Hsiao and Carbon, "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)
	*136	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)
	*137	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)
	*138	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
	*139	Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" <u>Proc. Natl. Acad. Sci. USA</u> 90:2551-2555 (March 1993)
	*140	Jakobovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" <u>Nature</u> 362:255-258 (March 18, 1993)
	*141	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
	*142	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977)
ac	*143	Jones, P.T. et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
	*144	Kaiser et al., "Media" <u>Methods in Yeast Genetics</u> (Appendix A), 1994 edition, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press pps. 207-210 (1994)

Examiner

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

1646
To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cu	*145	Keown et al., "Methods for Transferring DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)
	*146	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast <i>trp1</i> Region" <u>Gene</u> 7:141-152 (1979)
	*147	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
	*148	Kohler, G. and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)
	*149	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
	*150	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)
	*151	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
	*152	Lalmins et al., "Osmotic Control of <i>kdp</i> Operon Expression in <i>Escherichia Coli</i> " <u>Proc. Natl. Acad. Sci. USA</u> 78(1):464-468 (Jan 1981)
	*153	Lerner, "Antibodies of predetermined specificity in biology and medicine" <u>Advances in Immunology</u> 36:1-44 (1984)
	*154	Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P432) p. 115 (1991)
	*155	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
	*156	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)
	*157	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
	*158	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)
	*159	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" <u>Molecular & Cellular Biology</u> 3(6):1108-1122 (June 1983)
	*160	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
	*161	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
	*162	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- α Activation" <u>J. Immunol.</u> 153:5274-5284 (1994)
	*163	Maeda et al., "Production of Human α -interferon in Silkworm Using a Baculovirus Vector" <u>Nature</u> 315:592-594 (June 13, 1985)
cu	*164	Mage et al., "Preparation of Fab and F(ab') ₂ Fragments from Monoclonal Antibodies" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 79-97 (1987)

Examiner

C. M. L.

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

1646
To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

SEP 20 2001

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

an	*165	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
	*166	<u>Mammalian Cell Biotechnology: A Practical Approach</u> , M. Butler, ed., IRL Press (1991)
an	*167	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
	*168	Mantei et al., "Rabbit β -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
	*169	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*170	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	*171	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	*172	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
	*173	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)
	*174	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)
	*175	Mather, J.P., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
	*176	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" <u>Methods in Enzymology</u> 65:499-560 (1980)
	*177	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)
	*178	Messing et al., "A System for Shotgun DNA Sequencing" <u>Nucleic Acids Research</u> 9(2):309-321 (1981)
	*179	Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" <u>Genetic Engineering</u> , Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)
an	*180	Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (1983)
	*181	Mongkolsapaya et al., "Cutting Edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL" <u>Journal of Immunology</u> 160(1):3-6 (1998)
an	*182	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
	*183	Moran et al., "Glycophospholipid membrane anchor attachment. Molecular analysis of the cleavage/attachment-site" <u>Journal of Biological Chemistry</u> 266(2):1250-1257 (Jan 15, 1991)
an	*184	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)

Examiner

Clem M. K.

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

1646
~~To Be Assigned~~

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*185	Morrison et al., "Transfer and expression of immunoglobulin genes" <u>Annual Review of Immunology</u> 2:239-256 (1984)
*186	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)
*187	Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" <u>Science</u> 209:1422-1427 (Sep 1980)
*188	Munro, "Uses of chimaeric antibodies" <u>Nature</u> 312:597 (1984)
*189	Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)
*190	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)
*191	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
*192	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
*193	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)
*194	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
*195	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)
*196	Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" <u>Molecular & Cellular Biology</u> 4(7):1293-1305 (July 1984)
*197	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)
*198	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)
*199	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
*200	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
*201	Pavlakakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7398-7402 (December 1981)
*202	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)
*203	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)
*204	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P439) p. 118 (1991)

Examiner

Clare M. P.

Date Considered

9/10/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

 U.S. Dept. of Commerce
 Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001


Group

1646
~~To Be Assigned~~

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

An	*205	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
OIP	*206	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
SEP 20 2001	*207	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
PATENT & TRADEMARK OFFICE	*208	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
	*209	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)
	*210	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" <u>Euro. Cytokine Network</u> (abstract No. 82) 7:210 (April-Jun 1996)
	*211	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" <u>Programmed Cell Death Meeting</u> (abstract only) pps. 127 (20-24 September 1995)
	*212	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 β Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)
	*213	Reyes et al., "Expression of Human β -interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" <u>Nature</u> 297:598-601 (June 17, 1982)
	*214	Rice and Baltimore, "Regulated expression of an immunoglobulin κ gene introduced into a mouse lymphoid cell line" <u>Proc. Natl. Acad. Sci. USA</u> 79:7862-7865 (1982)
	*215	Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-329 (Mar 24, 1988)
	*216	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)
	*217	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
	*218	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
	*219	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
	*220	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)
	*221	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
	*222	Sharon et al., "Expression of a V μ C κ chimaeric protein in mouse myeloma cells" <u>Nature</u> 309:364-367 (1984)
	*223	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)
An	*224	Sheikh et al., "p53-dependent and -independent Regulation of the Death Receptor KILLER/DR5 Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor α " <u>Cancer Research</u> 58:1593-1598 (1998)

Examiner



Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

16.46
~~To Be Assigned~~

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

*225	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
*226	Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" <u>Cell</u> 20:269-281 (June 1980)
*227	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
*228	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)
*229	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" <u>Journal of Biological Chemistry</u> 266:14163-14166 (1991)
*230	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
*231	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
*232	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" <u>Cell</u> 76:959-962 (1994)
*233	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry & Biophysics</u> 259(1):52-57 (1987)
*234	Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" <u>J. Molec. Appl. Genet.</u> 1:327-341 (1982)
*235	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
*236	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)
*237	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)
*238	Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" <u>Molecular & Cellular Biology</u> 5:410-413 (1985)
*239	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
*240	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
*241	Tartaglia et al., "A novel domain within the 55 kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)
*242	Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)
*243	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
*244	Tewari et al., "Yama/CPP32 β , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)


Examiner

Claus M. Kof

Date Considered

9/17/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1110P1C1	Serial No. 09/887,879
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 21 Jun 2001	Group 1646 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
an	*245	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)			
	*246	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)			
	*247	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)			
	*248	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)			
	*249	Tissue Culture, Kruse and Patterson, eds., New York:Academic Press (1973)			
	*250	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)			
an	*251	Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" <u>Nature</u> 339:68-70 (1989)			
	*252	Treanor et al., "Characterization of a multicomponent receptor for GDNF" <u>Nature</u> 382:80-83 (1996)			
an	*253	Tschumper and Carbon, "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)			
	*254	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)			
	*255	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)			
	*256	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)			
	*257	Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" <u>Bio/Technology</u> 8:135-139 (1990)			
	*258	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)			
	*259	Verhoeven, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)			
	*260	Verma et al., "Rel/NF-KB/IkB Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)			
	*261	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)			
	*262	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)			
	*263	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" <u>Nature</u> 356:314-317 (1992)			
an	*264	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)			
Examiner				Date Considered 9/17/02	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1110P1C1

Serial No.

09/887,879

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

21 Jun 2001

Group

~~To Be Assigned~~

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.